The Effect of Abemaciclib Plus Fulvestrant on Overall Survival in Hormone Receptor–Positive, ERBB2-Negative Breast Cancer That Progressed on Endocrine Therapy—MONARCH 2

Authors:

Top Cited Papers
Open Access
Abstract
Most patients with metastatic breast cancer have tumors that are hormone receptor (HR)-positive and are initially treated with endocrine therapy (ET).1-4 Although ET is an efficacious and well-tolerated therapy in most patients, resistance to ET and subsequent disease progression remains a major challenge.2 In an effort to improve treatment options, cyclin-dependent kinase 4 and 6 (CDK4 and CDK6) inhibitors in combination with ET have emerged as a standard-of-care treatment for patients with HR-positive, ERBB2 (formerly HER2)-negative advanced breast cancer (ABC) (eg, inoperable locally advanced or metastatic breast cancer).5-8

This publication has 27 references indexed in Scilit: